RICHLAND, Wash.--(BUSINESS WIRE)--July 6, 2006--IsoRay Medical, Inc.'s collaboration with Idaho National Laboratory took a major step June 27 when testing began to demonstrate production of Cesium-131(TM), the company’s proprietary isotope currently used to treat prostate cancer.
